Focused on patients. Driven by science.
AVEO is committed to bettering the lives of patients with cancer through original drug development, as well as purposeful partnerships and acquisitions.
Our pipeline
Our goal is to grow into a global oncology leader with a strong foundational portfolio that provides solutions to unmet needs in the cancer community.
AVEO aims to leverage its existing collaborations and partnerships and enter into new strategic collaborations and partnerships to continue to advance each of its product candidates.
These are investigational drugs and/or investigational indications that have not been approved by the US Food and Drug Administration (FDA).
| Candidates | Research Areas | Stage | Marketed | Collaboration Partner | |||
| Pre-clinical | Phase I | Phase II | Phase III | ||||
| Tivozanib (VEGFR, Small molecule) | RCC | ||||||
| Ficlatuzumab* (Anti-HGF/c-MET IgG1 mAb) | HPV negative R/M HNSCC |  | |||||
| AV-380 (anti-GDF IgG1 mAb) | Cancer Cachexia | ||||||
| AV-203 (anti-ERBB3 lgG1 mAb) | Solid Tumor | ||||||
| AV-353 (Anti-Notch 3 mAb) | Multiple Myeloma | ||||||
| LR19155 (anti-LILRB1 IgG4 mAb) | Solid Tumor | ||||||
| LR20011 (microbiome) | Solid Tumor | GENOME & Co South Korea† | |||||
| LR19129 (WT1 target fusion protein) | Solid Tumor | CUE BIOPHARMA Asia-Pacific† | |||||
| LR19023 (Target undisclosed, Allo-CAR-T) | Solid Tumor | ||||||
| LR19127 (HPV target fusion protein) | HNSCC | CUE BIOPHARMA Asia-Pacific† | |||||
| LR19125 (Cancer vaccine) | NSCLC | PDC* line pharma South Korea† | |||||
| LR22011 (Target undisclosed, iPSC-CAR-NK) | Unspecified cancer | ||||||
*Fast track designation
†in-license
FOTIVDA in rrRCC
FOTIVDA is a next-generation vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It was approved by the FDA in March 2021 for the treatment of adults with relapsed or refractory advanced renal cell carcinoma (RCC) after 2 or more systemic therapies.
Learn moreFiclatuzumab is a potent, humanized IgG1 monoclonal antibody that targets hepatocyte growth factor, or HGF.
Learn moreAV-380 for the potential treatment and/or prevention of cancer cachexia currently undergoing a Phase 1b clinical study.
Learn moreEvolution of the HUMAN RESPONSE® Platform
Our portfolio originated in the HUMAN RESPONSE® Platform. This platform was designed to drive rapid development and resulted in our clinical candidates. Today, we are collaborating with the LG Chem Innovation Center to expand and advance the AVEO pipeline.